# A Study on the Combined Use of Tocilizumab and Flupentixol-Melitracen in the Treatment of Thyroid-Associated Ophthalmopathy

> **NCT06927375** · PHASE4 · RECRUITING · sponsor: **Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University** · enrollment: 60 (estimated)

## Conditions studied

- Thyroid-Associated Ophthalmopathy

## Interventions

- **DRUG:** Tocilizumab(400mg) combined with Flupentixol Melitracen(0.5mg:10mg)
- **DRUG:** Tocilizumab(400mg)

## Key facts

- **NCT ID:** NCT06927375
- **Lead sponsor:** Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-12-12
- **Primary completion:** 2025-11-12
- **Final completion:** 2026-03-12
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2025-04-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06927375

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06927375, "A Study on the Combined Use of Tocilizumab and Flupentixol-Melitracen in the Treatment of Thyroid-Associated Ophthalmopathy". Retrieved via AI Analytics 2026-07-04 from https://api.ai-analytics.org/clinical/NCT06927375. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*